Abstract
Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.
| Original language | English |
|---|---|
| Pages (from-to) | R351-R364 |
| Journal | Endocrine-Related Cancer |
| Volume | 25 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 1 2018 |
Fingerprint
Keywords
- Neuroendocrine tumors
- Pasireotide
- Somatostatin analogs
- Somatostatin receptors
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Oncology
- Endocrinology
- Cancer Research
Cite this
Pasireotide in the treatment of neuroendocrine tumors : A review of the literature. / Vitale, Giovanni; Dicitore, Alessandra; Sciammarella, Concetta; Di Molfetta, Sergio; Rubino, Manila; Faggiano, Antongiulio; Colao, Annamaria.
In: Endocrine-Related Cancer, Vol. 25, No. 6, 01.06.2018, p. R351-R364.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Pasireotide in the treatment of neuroendocrine tumors
T2 - A review of the literature
AU - Vitale, Giovanni
AU - Dicitore, Alessandra
AU - Sciammarella, Concetta
AU - Di Molfetta, Sergio
AU - Rubino, Manila
AU - Faggiano, Antongiulio
AU - Colao, Annamaria
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.
AB - Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.
KW - Neuroendocrine tumors
KW - Pasireotide
KW - Somatostatin analogs
KW - Somatostatin receptors
UR - http://www.scopus.com/inward/record.url?scp=85047477909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047477909&partnerID=8YFLogxK
U2 - 10.1530/ERC-18-0010
DO - 10.1530/ERC-18-0010
M3 - Review article
AN - SCOPUS:85047477909
VL - 25
SP - R351-R364
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
SN - 1351-0088
IS - 6
ER -